ABOUT THIS STUDY
- Patients must have low back pain with a neuropathic pain component between 3 months and 12 months duration prior to entering the study.
- Patients must have a score of at least 19 on the PainDetect questionnaire and at least 4 on the Standardized Evaluation of Pain (StEP) scale at screening.
- Patients must have a mean pain numerical rating scale (NRS) score of 4 or more during the one week screening period.
- Patients must have failed to respond to standard analgesic therapy (e.g. non-steroidal anti-inflammatory drugs [NSAIDs]) and/or one treatment for neuropathic pain (e.g. tricyclics, serotonin-norepinephrine re-uptake inhibitors [SNRIs]) prior to entering the study).
- A diagnosis of depression or a Hospital Anxiety and Depression Scale (HADS) score of >
15 on the depression sub-scale only.
- Patients with a history of renal impairment or who have reduced renal function at
baseline (Creatinine Clearance < 60 mL/min).
- Patients who have previously taken pregabalin or gabapentin within 6 months prior to
entering the study.
- Patients who have undergone previous surgery for back pain.
- Patients who are using high doses of opioid medication (morphine > 60 mg per day).
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.